The new information was garnered using colorectal and pancreatic cancer cell lines.
Redx concluded that cancer cells carrying RNF43 mutations or RSPO fusions were sensitive to RXC004 in its tests.
As such, the company believes it would be most effective as a single therapy in patients with cancers carrying those markers.
This, it added, would support by a genetically-defined patient selection strategy for ongoing RXC004 clinical studies.
A phase I/IIa trial of the porcupine inhibitor is set to resume in the first half of next year in patients with what are described as “advanced malignancies”.
A poster summarising the latest data will be presented to the National Cancer Research Institute in Glasgow from noon Monday.
"We are delighted to showcase some of the fantastic science happening at Redx,” said the company’s chief medical officer, Richard Armer.
“We are encouraged by the preclinical data presented at the NCRI, which demonstrates the exquisite sensitivity of specific genetically defined cancer models to our Porcupine inhibitor, RXC004.
“The strength of these data highlight some of the broad and multiple options available for the future development of this programme as we look to re-enter the clinic in the first half of 2019."